Abstract
Hepatocellular carcinoma (HCC), the most common primary liver tumor, is notoriously resistant to systemic therapies, and often recurs even after aggressive local therapies. HCCs rely on the formation of new blood vessels for growth, and VEGF is critical in this process. A hallmark of new vessel formation in tumors is their structural and functional abnormality. This leads to an abnormal tumor microenvironment characterized by low oxygen tension. The liver is perfused by both arterial and venous blood and the resulting abnormal microenvironment selects for more-aggressive malignancies. Anti-VEGF therapy with sorafenib was the first systemic therapy to demonstrate improved survival in patients with advanced-stage HCC. This important development in the treatment of HCC raises hope as well as critical questions on the future development of targeted agents including other antiangiogenic agents, which hold promise to further increase survival in this aggressive disease.
Key Points
-
Hepatocellular carcinoma (HCC) is a heterogeneous disease with multiple etiologies that is uniformly fatal when unresectable; other malignant liver tumors include cholangiocarcinoma, angiosarcoma, hemangioendothelioma and hepatoblastoma
-
The growth of HCCs depends on their ability to recruit blood vessels by forming new vessels through sprouting (angiogenesis) and potentially by recruiting proangiogenic bone marrow-derived cells
-
Tumor neovasculature is highly abnormal, both structurally and functionally because of overexpression of VEGF; other molecules are also involved and may be important therapeutic targets
-
Sorafenib was developed as a VEGFR2, VEGFR3, PDGFR-β, and Raf/MEK/ERK signaling inhibitor; despite being standard of care in advanced-stage HCC, its mechanism of action remains unknown
-
Antiangiogeneic agents can transiently prune and normalize the tumor vasculature and improve the outcome of other treatments (chemotherapy, radiation) given during the normalization window
-
Circulating and imaging markers may be useful as pharmacodynamic end points, and may hold promise as potential surrogate and predictive markers for antiangiogenic therapy
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
08 April 2011
In the version of this article initially published online the acknowledgements section was missing. The text should have read: "The authors acknowledge support by the National Institutes of Health (P01CA80124, R01CA115767, R21CA139168, M01RR01066, Federal Share/NCI Proton Beam Program Income Grants); by a Department of Defense Breast Cancer Research Innovator award (W81XWH-10-1-0016) and by an American Cancer Society Research Grant (RSG-11-073-01-TBG)." The error has been corrected for the print, HTML and PDF versions of the article.
References
Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917 (2010).
Thomas, M. B. & Zhu, A. X. Hepatocellular carcinoma: the need for progress. J. Clin. Oncol/ 23, 2892–2899, (2005).
Fong, Y., Kemeny, N. & Lawrence, T. S. in Cancer, Principles and Practice of Oncology 6th edn (eds DeVita, V. T., Hellman, S. & Rosenberg, S. A.) 1162–1203 (Lippincott Williams and Wilkins, Philadelphia, PA, USA, 2001).
Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273–286 (2007).
Van de Veire, S. et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141, 178–190 (2010).
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
Sun, H. C. & Tang, Z. Y. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J. Cancer Res. Clin. Oncol. 130, 307–319 (2004).
Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).
Jain, R. K. Taming vessels to treat cancer. Sci. Am. 298, 56–63 (2008).
Naugler, W. E. & Karin, M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 14, 109–119 (2008).
Zhu, A. X. et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 27, 3027–3035 (2009).
Abou-Alfa, G. K. et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 4293–4300 (2006).
Yang, Z. F. & Poon, R. T. Vascular changes in hepatocellular carcinoma. Anat. Rec. (Hoboken) 291, 721–734 (2008).
Fukumura, D., Yuan, F., Monsky, W. L., Chen, Y. & Jain, R. K. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am. J. Pathol. 151, 679–688 (1997).
Wu, X. Z., Xie, G. R. & Chen, D. Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 22, 1178–1182 (2007).
Jain, R. K., Tong, R. T. & Munn, L. L. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 67, 2729–2735 (2007).
LeCouter, J. et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299, 890–893 (2003).
Lichtenberger, B. M. et al. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 140, 268–279 (2010).
Fukumura, D. et al. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 61, 6020–6024 (2001).
Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249–257 (2000).
Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368–4380 (2002).
Fukumura, D., Kashiwagi, S. & Jain, R. K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 6, 521–534 (2006).
Fukumura, D. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715–725 (1998).
Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737–744 (2000).
Amarapurkar, A. D., Amarapurkar, D. N., Vibhav, S. & Patel, N. D. Angiogenesis in chronic liver disease. Ann. Hepatol. 6, 170–173 (2007).
Ho, J. W. et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 44, 836–843 (2006).
Jain, R. K. Molecular regulation of vessel maturation. Nat. Med. 9, 685–693 (2003).
Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669–676 (2003).
Semela, D. & Dufour, J. F. Angiogenesis and hepatocellular carcinoma. J. Hepatol. 41, 864–880 (2004).
Roberts, L. R. & Gores, G. J. Emerging drugs for hepatocellular carcinoma. Expert Opin. Emerg. Drugs 11, 469–487 (2006).
Mas, V. R., Maluf, D. G., Archer, K. J., Yanek, K. C. & Fisher, R. A. Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. Transplantation 84, 1262–1271 (2007).
Poon, R. T. et al. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am. J. Surg. 182, 298–304 (2001).
Poon, R. T. et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann. Surg. 233, 227–235 (2001).
Dhar, D. K. et al. Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. Anticancer Res. 22, 379–386 (2002).
El-Assal, O. N. et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27, 1554–1562 (1998).
Park, Y. N., Kim, Y. B., Yang, K. M. & Park, C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch. Pathol. Lab. Med. 124, 1061–1065 (2000).
Yamaguchi, R. et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28, 68–77 (1998).
Li, X. M., Tang, Z. Y., Zhou, G., Lui, Y. K. & Ye, S. L. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 17, 13–17 (1998).
Yao, D. F. et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 4, 220–226 (2005).
Zhou, J. et al. Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J. Cancer Res. Clin. Oncol. 126, 57–61 (2000).
Poon, R. T. et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg. 91, 1354–1360 (2004).
Chao, Y. et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann. Surg. Oncol. 10, 355–362 (2003).
Tamesa, T. et al. High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma. Hepatogastroenterology 56, 1122–1126 (2009).
Xiong, H. Q. et al. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest. New Drugs 22, 459–466 (2004).
Li, X., Feng, G. S., Zheng, C. S., Zhuo, C. K. & Liu, X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J. Gastroenterol. 10, 2878–2882 (2004).
Shim, J. H. et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci. 99, 2037–2044 (2008).
Sergio, A. et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am. J. Gastroenterol. 103, 914–921 (2008).
Poon, R. T. et al. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann. Surg. Oncol. 14, 1835–1845 (2007).
Cui, J., Dong, B. W., Liang, P., Yu, X. L. & Yu, D. J. Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection. World J. Gastroenterol. 10, 1533–1536 (2004).
Hu, J. et al. High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. J. Cancer Res. Clin. Oncol. 135, 1359–1367 (2009).
Moon, J. I. et al. Expression of vascular endothelial growth factor (VEGF) family members and prognosis after hepatic resection in HBV-related hepatocellular carcinoma [Korean]. Korean J. Hepatol. 14, 185–196 (2008).
Jeng, K. S. et al. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J. Gastroenterol. 10, 643–648 (2004).
Jeng, K. S. et al. Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection? World J. Gastroenterol. 10, 676–681 (2004).
Ho, M. C. et al. Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett. 250, 237–249 (2007).
Wada, H. et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int. 26, 414–423 (2006).
Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25–34 (2009).
McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA 104, 19936–19941 (2007).
Dufour, J. F. et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist 15, 1198–1204 (2010).
Allegra, C. J. et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol. 29, 11–16 (2010).
Van Cutsem, E., Lambrechts, D., Prenen, H., Jain, R. K. & Carmeliet, P. Lessons from the adjuvant bevacizumab trial in colon cancer: what next? J. Clin. Oncol. 29, 1–4 (2010).
Arora, A. & Scholar, E. M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315, 971–979 (2005).
Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
Pawson, T. Regulation and targets of receptor tyrosine kinases. Eur. J. Cancer 38 (Suppl. 5), S3–S10 (2002).
Faivre, S. et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 10, 794–800 (2009).
Hoda, D. et al. Phase II study of sunitinib malate in adult patients with metastatic or surgically unresectable hepatocellular carcinoma (HCC) [abstract]. Proc. 2008 Gastrointestinal Cancers Symp. a267 (2008).
Koeberle, D. et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 15, 285–292 (2010).
Demetri, G. D. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329–1338 (2006).
Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590 (2009).
Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232–239 (2009).
Zhu, A. X. et al. A phase II study of ramucirumab as first-line monotherapy in patients with advanced hepatocellular carcinoma [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4083 (2010).
Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat. Med. 7, 987–989 (2001).
Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145–147 (2004).
Siegel, A. B. et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 26, 2992–2998 (2008).
Zhu, A. X. et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 1898–1903 (2006).
Hsu, C. H. et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br. J. Cancer 102, 981–986 (2010).
Sun, W. et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma: a phase II study [abstract]. J. Clin. Oncol. 25 (18 Suppl.), a4574 (2007).
Malka, D. et al. Bevacizumab in patients with advanced hepatocellular carcinoma: preliminary results of a phase II study with circulating endothelial cell monitoring [abstract]. J. Clin. Oncol. 25 (18 Suppl.), a4570 (2007).
Thomas, M. B. et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol. 27, 843–850 (2009).
Albert, D. H. et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 5, 995–1006 (2006).
Toh, H. et al. Linifanib phase II trial in patients with advanced hepatocellular carcinoma [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4038 (2010).
Wedge, S. R. et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65, 4389–4400 (2005).
Alberts, S. R. et al. NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma—interim review of toxicity [abstract]. Proc. 2007 Gastrointestinal Cancers Symp. a186 (2007).
Yau, C. C. et al. A phase I study of pazopanib in patients with advanced hepatocellular carcinoma [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a3561 (2009).
Wood, J. M. et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60, 2178–89 (2000).
Drevs, J. et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 62, 4015–4022 (2002).
Koch, I. et al. Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics of PTK787/ZK 222584 in patients with unresectable hepatocellular carcinoma [abstract]. J. Clin. Oncol. 23 (16 Suppl.), a4134 (2005).
Yau, T. et al. Phase 1–2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. Cancer 116, 5022–5029 (2010).
Huynh, H. et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res. 14, 6146–6153 (2008).
Ohta, M. et al. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surg. Today 39, 1046–1053 (2009).
Raoul, J. L. et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a4577 (2009).
Kanai, F. et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 67, 315–324 (2011).
Eder, J. P. et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin. Cancer Res. 16, 3507–3516 (2010).
Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698–711 (2008).
Zhu, A. X., Duda, D. G., Sahani, D. V. & Jain, R. K. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience and correlative studies. Cancer J. 15, 263–268 (2009).
Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205–216 (2000).
Faivre, S. J., Bouattour, M., Dreyer, C. & Raymond, E. Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. J. Clin. Oncol. 27, e248–e250 (2009).
Bruix, J. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35, 421–430 (2001).
Miller, J. C., Pien, H. H., Sahani, D., Sorensen, A. G. & Thrall, J. H. Imaging angiogenesis: applications and potential for drug development. J. Natl Cancer Inst. 97, 172–187 (2005).
Suzuki, C. et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 28, 329–344 (2008).
Forner, A. et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115, 616–623 (2009).
Jain, R. K. et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6, 327–338 (2009).
Farazi, P. A. & DePinho, R. A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674–687 (2006).
Rafii, S., Lyden, D., Benezra, R., Hattori, K. & Heissig, B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2, 826–835 (2002).
Zhu, A. X. et al. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value. Clin. Cancer Res. 17, 918–927 (2011).
Kumar, R. et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer 101, 1717–1723 (2009).
Toh, H., Chen, P. & Carr, B. et al. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): interim analysis [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a4581 (2009).
Shao, Y. Y. et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 116, 4590–4596 (2010).
DePrimo, S. E. et al. Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): analysis of correlations with outcome and tumor imaging parameters [abstact]. J. Clin. Oncol. 26 (Suppl.), a4593 (2008).
Boige, V. et al. Circulating endothelial cells (CECs) and angiogenic proteins monitoring in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with bevacizumab [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a4597 (2009).
Kaseb, A. O. et al. Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4046 (2010).
Shao, Y. et al. Prognostic values of baseline circulating endothelial progenitor level for advanced hepatocellular carcinoma (HCC) patients under antiangiogenic therapy [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4063 (2010).
Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391–400 (2004).
Hood, J. D. et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404–2407 (2002).
Gagnon, M. L. et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc. Natl Acad. Sci. USA 97, 2573–2578 (2000).
Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932–936 (2005).
Gridley, T. Vascular biology: vessel guidance. Nature 445, 722–723 (2007).
Williams, C. K., Li, J. L., Murga, M., Harris, A. L. & Tosato, G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107, 931–939 (2006).
Leslie, J. D. et al. Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 134, 839–844 (2007).
Ridgway, J. et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444, 1083–1087 (2006).
Hellstrom, M. et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445, 776–780 (2007).
Vincent, F. et al. Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. Cancer Res. 69, 2853–2860 (2009).
Phung, T. L. et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10, 159–170 (2006).
Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436–444 (2008).
Pikarsky, E. et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461–466 (2004).
He, G. et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17, 286–297 (2010).
Park, E. J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197–208 (2010).
Zhang, W. et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 16, 3420–3430 (2010).
Sakurai, T. et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14, 156–165 (2008).
Carmi, Y. et al. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J. Immunol. 183, 4705–4714 (2009).
Germano, G., Allavena, P. & Mantovani, A. Cytokines as a key component of cancer-related inflammation. Cytokine 43, 374–379 (2008).
Mizukami, Y. et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med. 11, 992–997 (2005).
Kubo, F. et al. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann. Surg. Oncol. 12, 800–807 (2005).
Brat, D. J., Bellail, A. C. & Van Meir, E. G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro. Oncol. 7, 122–133 (2005).
Li, W., Gomez, E. & Zhang, Z. Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 26, 527–533 (2007).
Grunewald, M. et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124, 175–189 (2006).
Mansuroglu, T. et al. Expression of stem cell factor and its receptor c-Kit during the development of intrahepatic cholangiocarcinoma. Lab. Invest. 89, 562–574 (2009).
Wang, B., Gao, Z. Q. & Yan, X. Correlative study of angiogenesis and dynamic contrast-enhanced magnetic resonance imaging features of hepatocellular carcinoma. Acta Radiol. 46, 353–358 (2005).
d'Assignies, G. et al. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology 250, 407–416 (2009).
Sahani, D. V., Holalkere, N. S., Mueller, P. R. & Zhu, A. X. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. Radiology 243, 736–743 (2007).
Zhu, A. X., Holalkere, N. S., Muzikansky, A., Horgan, K. & Sahani, D. V. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 13, 120–125 (2008).
Liaw, J V. et al. Tumor vascularity assessment in hepatocellular carcinoma and disease free caudate and spleen before and after targeted therapy using a distributed parameter model [abstract]. Presented at RSNA 2009.
Jarnagin, W. R. et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann. Oncol. 20, 1589–1595 (2009).
Sorensen, A. G. et al. A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 69, 5296–5300 (2009).
Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83–95 (2007).
Battistella, M. et al. Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma. J. Eur. Acad. Dermatol. Venereol. 24, 199–203 (2010).
Lassau, N. et al. Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment. Target. Oncol. 5, 53–58 (2010).
Acknowledgements
The authors acknowledge support by the National Institutes of Health (P01CA80124, R01CA115767, R21CA139168, M01RR01066, Federal Share/NCI Proton Beam Program Income Grants); by a Department of Defense Breast Cancer Research Innovator award (W81XWH-10-1-0016) and by an American Cancer Society Research Grant (RSG-11-073-01-TBG).
Author information
Authors and Affiliations
Contributions
A. X. Zhu and R. K. Jain contributed equally to the preparation of this manuscript. All authors contributed to researching data for the article, discussions of content, writing of the manuscript and to review and editing of the article before submission.
Corresponding author
Ethics declarations
Competing interests
A. X. Zhu declares he is a consultant for Novartis, Pfizer and Sanofi-Aventis. He also receives grant/research support from Bayer. R. K. Jain declares he is a consultant for Astellas, AstraZeneca, MedImmune, Dyax, Noxxon, Genzyme, Regeneron, FibroGen, MorphoSys, SynDevRx, Novartis, Bayer and Pfizer. He receives honoraria from Genzyme and grant/research support from AstraZeneca, MedImmune and Dyax. He is a stock holder or Director at SynDevRx. The other authors declare no competing interests.
Supplementary information
Supplementary Table 1
Angiogenesis activators and inhibitors* (DOC 60 kb)
Supplementary Table 2
Phase II studies of sunitinib in advanced-stage hepatocellular carcinoma (DOC 40 kb)
Supplementary Table 3
Phase II studies of bevacizumab in advanced-stage hepatocellular carcinoma (DOC 41 kb)
Rights and permissions
About this article
Cite this article
Zhu, A., Duda, D., Sahani, D. et al. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 8, 292–301 (2011). https://doi.org/10.1038/nrclinonc.2011.30
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.30
This article is cited by
-
CircSNX6 promotes proliferation, metastasis, and angiogenesis in hepatocellular carcinoma via miR-383-5p/VEGFA signaling pathway
Scientific Reports (2024)
-
Targeting the SphK1/S1P/PFKFB3 axis suppresses hepatocellular carcinoma progression by disrupting glycolytic energy supply that drives tumor angiogenesis
Journal of Translational Medicine (2024)
-
USP22 upregulates ZEB1-mediated VEGFA transcription in hepatocellular carcinoma
Cell Death & Disease (2023)
-
Secukinumab plays a synergistic role with starvation therapy in promoting autophagic cell death of hepatocellular carcinoma via inhibiting IL-17A-increased BCL2 level
In Vitro Cellular & Developmental Biology - Animal (2023)
-
Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
BMC Gastroenterology (2023)